MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Free Cash flow
-$17,604K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from sales or maturitie...
    • Proceeds from issuance of common...
    • Stock based compensation expense
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Purchases of investments
    • Offering costs incurred and paid...
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-25,867
-20,196
-20,919
-20,283
Reduction in the carrying amount of rou assets, operating
402
393
385
377
Reduction in the carrying amount of rou assets, finance
80
80
80
80
Stock based compensation expense
5,690
2,755
2,713
2,651
Depreciation and amortization expense
74
73
73
73
Non-cash gain on long-term investment
-
-
0
0
Net realized gain on investments in u.s. treasury securities
-
-
17
-
Non-cash gain on long-term investment in preferred stock
0
-
-
-
Amortization of premium (accretion of discount) on investments in u.s. treasury securities
-21
42
-5
-60
Prepaid expenses and other current assets
-898
1,119
1,578
-2,140
Accounts payable
828
-1,596
200
-15,268
Accrued expenses and other current liabilities
689
-1,092
-619
996
Lease liabilities, operating
-412
-402
-394
-381
Lease liabilities, finance
0
2
-8
8
Net cash used in operating activities
-17,597
-21,144
-20,079
-29,547
Proceeds from sales or maturities of investments
26,240
27,495
38,327
35,300
Purchases of investments
11,969
-
140,016
0
Purchase of property and equipment
7
35
0
289
Net cash provided by (used in) investing activities
14,264
27,460
-101,689
35,011
Proceeds from issuance of common stock under the atm program, pre-funded warrants and warrants to purchase common stock upon may 2025 private placement offering, gross
24,857
143
-1
101
Offering costs incurred and paid to third parties in association with the atm program
804
-
-
-
Proceeds from exercise of common warrants
0
2,446
-
-
Proceeds from issuance of common stock, pre-funded warrants and warrants to purchase common stock upon may 2025 private placement offering
-
-
-
0
Proceeds from issuance of common stock, pre-funded warrants and warrants to purchase common stock upon may 2025 private placement
-
-
79,999
-
Proceeds from issuance of common stock under the atm program, pre-funded warrants and warrants to purchase common stock upon may 2025 private placement offering, gross
0
-
-
-
Third-party commissions and offering costs incurred upon may 2025 private placement offering
0
-
0
0
Proceeds from exercise of stock options
320
9
25
34
Proceeds from issuance of common stock and pre-funded warrants to purchase common stock upon october 2025 financing transactions
-
-
153,750
-
Proceeds from common stock issuances under 2023 espp
143
-
-
-
Third-party commissions and offering costs incurred upon october 2025 financing transactions
-
25
9,833
-
Payments on finance leases
142
121
169
83
Net cash provided by financing activities
24,399
2,452
143,772
52
Net change in cash, cash equivalents and restricted cash
21,066
8,768
22,004
5,516
Cash, cash equivalents and restricted cash at beginning of period
75,016
66,248
44,244
38,266
Cash, cash equivalents and restricted cash at end of period
96,082
75,016
66,248
44,244
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock under the...$24,857K (14521.76%↑ Y/Y)Proceeds from sales ormaturities of investments$26,240K (-17.74%↓ Y/Y)Proceeds from exercise ofstock options$320K Proceeds from commonstock issuances under...$143K (-15.88%↓ Y/Y)Net cash provided byfinancing activities$24,399K (-66.56%↓ Y/Y)Net cash provided by(used in) investing...$14,264K (160.51%↑ Y/Y)Canceled cashflow$946K Canceled cashflow$11,976K Net change in cash,cash equivalents and...$21,066K (4459.74%↑ Y/Y)Canceled cashflow$17,597K Offering costs incurredand paid to third...$804K Payments on financeleases$142K (-49.47%↓ Y/Y)Stock basedcompensation expense$5,690K (-15.93%↓ Y/Y)Prepaid expenses andother current assets-$898K (-135.00%↓ Y/Y)Accounts payable$828K (-93.87%↓ Y/Y)Accrued expenses andother current...$689K (114.29%↑ Y/Y)Reduction in the carryingamount of rou assets,...$402K (-44.86%↓ Y/Y)Reduction in the carryingamount of rou assets,...$80K (-50.00%↓ Y/Y)Depreciation andamortization expense$74K (-39.34%↓ Y/Y)Amortization of premium(accretion of discount) on...-$21K (54.35%↑ Y/Y)Purchases of investments$11,969K (-78.38%↓ Y/Y)Purchase of property andequipment$7K (-93.52%↓ Y/Y)Net cash used inoperating activities-$17,597K (64.04%↑ Y/Y)Canceled cashflow$8,682K Net loss-$25,867K (55.98%↑ Y/Y)Lease liabilities,operating-$412K (42.86%↑ Y/Y)

Lexeo Therapeutics, Inc. (LXEO)

Lexeo Therapeutics, Inc. (LXEO)